Eight months after receiving a broad federal license for importing
, a Norfolk research company is about to embark on a series of critical studies into a variety of medical and mental disorders, diseases and conditions.
Sanyal Biotechnology is already considering proposals for research campuses and planning its first clinical trial for this summer. The new venture potentially opens the door to significantly expanding national research being done on the medical benefits of cannabis.
It brings the company one step away from its main focus: pharmaceutical drug screening through preclinical trials of liver diseases, obesity and diabetes. But Rebecca Caffrey, co-founder and CEO of Sanyal, said the research possibilities with cannabis extracts are endless.
She said the federal license is the broadest ever issued to a U.S. company and allows it to import high-quality cannabis extracts not available in the